Skip to main content

Table 1 Outcomes on individual EQ-5D dimensions by treatment group

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

  Baseline Week 13 Week 25 Week 37 Week 49 Week 61
EQ-5D dimensions ENZA (n = 857), % PBO (n = 826), % P value ENZA (n = 809), % PBO (n = 624), % P value ENZA (n = 746), % PBO (n = 367), % P value ENZA (n = 671), % PBO (n = 267), % P value ENZA (n = 610), % PBO (n = 176), % P value ENZA (n = 523), % PBO (n = 117), % P value
Mobility
 Level 1 74.9% 74.7% 0.5940 74.7% 71.3% 0.3197 73.7% 70.8% 0.5823 70.4% 70.3% 0.8183 66.7% 30.9% 0.6454 68.5% 71.8% 0.7640
 Level 2 or 3 25.1% 25.3%   25.4% 28.8%   26.3% 29.1%   29.7% 29.7%   33.3% 69.1%   31.6% 28.3%  
Self-care
 Level 1 94.9% 93.8% 0.1726 93.9% 92.0% 0.2253 94.0% 90.6% 0.1034 92.4% 91.7% 0.2849 92.3% 92.0% 0.9186 6.9% 10.2% 0.0619
 Level 2 or 3 5.1% 6.2%   6.1% 8.0%   6.0% 9.3%   7.7% 8.3%   7.7% 8.0%   93.1% 89.7%  
Usual Activities
 Level 1 80.1% 80.5% 0.9685 74.9% 69.3% 0.0675 77.9% 71.8% 0.0262 76.2% 76.7% 0.3589 70.8% 71.8% 0.9266 72.7% 69.8% 0.6346
 Level 2 or 3 20.0% 19.5%   25.1% 30.6%   22.1% 28.2%   23.9% 23.4%   29.3% 28.2%   27.31% 30.2%  
Pain/Discomfort
 Level 1 55.8% 58.5% 0.4623 56.0% 47.8% 0.0051 59.8% 50.7% 0.0163 56.4% 47.6% 0.0475 52.6% 52.8% 0.6281 52.4% 53.9% 0.4483
 Level 2 or 3 44.3% 41.5%   44.1% 52.2%   40.3% 49.4%   43.5% 52.5%   47.5% 47.1%   47.6% 46.2%  
Anxiety/Depression
 Level 1 75.0% 72.9% 0.0690 74.4% 67.6% 0.0060 76.3% 71.0% 0.1610 75.9% 72.9% 0.5023 74.0% 68.8% 0.1762 70.8% 71.8% 0.7396
 Level 2 or 3 25.0% 27.2%   25.6% 32.4%   23.8% 29.1%   24.1% 27.0%   26.0% 31.3%   29.2% 28.2%  
  1. ENZA enzalutamide, PBO placebo
  2. Differences refer to the comparison between groups in the percentage of patients with (2 or 3) or without (1) problems in each dimension. They do not take into account whether patients are in level 2 or 3. There were very few patients at level 3 in any dimension, even at 61 weeks. P values refer only to the between-group differences